BridgeBio Pharma (BBIO) EBIT (2018 - 2026)

BridgeBio Pharma has disclosed EBIT across 9 years of filings, most recently posting -$106.0 million for Q1 2026.

• EBIT for Q1 2026 came in at -$106.0 million, down 1.52% year-over-year; the trailing twelve-month figure through Mar 2026 was -$525.0 million (up 24.75% YoY), and the FY2025 annual result was -$523.4 million, up 11.73% from the prior year.
• EBIT came in at -$106.0 million for Q1 2026 at BridgeBio Pharma, up from -$139.6 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $343000.0 in Q1 2024 to a low of -$226.0 million in Q4 2024.
• The 5-year median for EBIT is -$139.6 million (2025), against an average of -$137.8 million.
• Across the five-year window, EBIT surged 100.27% in 2024 and plunged 30529.15% in 2025, its largest moves.
• BridgeBio Pharma's EBIT stood at -$129.2 million in 2022, then plunged by 37.28% to -$177.4 million in 2023, then declined by 27.4% to -$226.0 million in 2024, then surged by 38.25% to -$139.6 million in 2025, then rose by 24.08% to -$106.0 million in 2026.
• The last three EBIT figures came in at -$106.0 million (Q1 2026), -$139.6 million (Q4 2025), and -$145.2 million (Q3 2025), per Business Quant data.